Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma
Edwin P. Hui, Brigette B. Y. Ma, K. C. Allen Chan, Charles M. L. Chan, Cesar S. C. Wong, Ka Fai To, Anthony W. H. Chan, Stewart Y. Tung, Wai-Tong Ng, Ashley C. Cheng, Victor H. F. Lee, Stephen L. Chan, Herbert H. F. Loong, Michael K. M. Kam, Sing-Fai Leung, Rosalie Ho, Frankie Mo, Roger K. C. Ngan and Anthony T. C. Chan
Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29413
In a prospective biomarker study of patients with nasopharyngeal cancer, plasma Epstein-Barr virus DNA is validated as the most significant prognostic biomarker for use in selecting high-risk patients for adjuvant therapy. The ERCC1 C118T genotype may help to identify a favorable subgroup of patients (approximately 7%) with plasma Epstein-Barr virus DNA-negative nasopharyngeal cancer who have an excellent prognosis and can be spared the toxicities of further therapy.